NCT00826722已完成不适用
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 1g Tablets Under Fasting Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- bioequivalence based on Cmax
研究概览
简要总结
The objective of this study was to prove the bioequivalence of Levetiracetam 1000 mg Tablets under fasted conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Levetiracetam or any comparable or similar product.
结局指标
主要结局
bioequivalence based on Cmax
时间窗: 10 days
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of Levetiracetam 1g Tablets Under Fed ConditionsSeizuresNCT00827320Roxane Laboratories26
已完成
不适用
Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed ConditionsSeizuresNCT00826787Roxane Laboratories29
已完成
不适用
Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting ConditionsSeizuresNCT00826865Roxane Laboratories27
已完成
1 期
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in ChineseHuman VolunteersNCT01618903UCB Pharma24
已完成
不适用
A Bioequivalence Study of Levetiracetam Versus KeppraHealthyNCT00926302Tri-Service General Hospital26